Bone Marrow Cell Engraftment of the Uterus and Genetic Studies of Reproductive Functioning

NCT ID: NCT01468935

Last Updated: 2019-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

79 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-10-31

Study Completion Date

2017-09-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

\- Some transplant recipients have been found to have cells in their uterus that come from the donor. Researchers want to study uterine tissue from three different groups of women: (1) healthy volunteers, (2) people who have had a stem cell transplant, and (3) people with rare diseases or conditions that affect reproduction. These samples will help researchers learn more about the way stem cells work in the reproductive tract.

Objectives:

\- To collect cells from the uterus to study how stem cells work in the reproductive tract.

Eligibility:

\- Women at least 18 years of age.

Design:

* Participants will be screened with a physical exam and medical history. They will also have blood and urine tests.
* Participants will have an endometrial biopsy to collect cells for study. The biopsy visit will take 1 to 2 hours.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Transplantation with hematopoietic cells has been used for a wide variety of blood disorders, but also for diseases like solid organ cancers. Interestingly, women who have had bone marrow transplants have been found to have donor tissue in their endometrium, which raises the possibility of cellular therapies using bone marrow derived cells for gynecologic indications. Donor engraftment does not appear to occur when transplantations were performed with stem cells collected from peripheral blood of the donor. Therefore, the subtype of cells from the bone marrow responsible for engraftment is not yet known, nor is the ideal transplantation regimen known.

The immediate aim of this tissue procurement protocol is to obtain endometrial (uterine) stem cells from many human volunteers in order to examine the biological properties of those cells. We will collect tissue from 3 primary groups of patients: normal controls, patients with rare diseases or reproductive disorders, and patients who have undergone hematopoietic stem cell transplant. Each volunteer will undergo an endometrial biopsy during an office visit. The endometrial tissue will then be studied for a better understanding of their biological properties, growth and differentiation. One specific area of interest is to study how hematopoietic transplantation impacts endometrial cell function. These endometrial cells will be analyzed in-depth in the laboratory to determine if they came from the donor or recipient, and if so, which specific populations of cells. Hematologic pre-transplant conditioning information will be correlated with these research studies to identify factors that may assist with the understanding of adult endometrial stem cell biology.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometriosis Stem Cell Transplant Healthy Volunteers

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Uterus Endometrium Bone Marrow Transplant Gynecology Healthy Volunteer HV Stem Cell Transplant Endometriosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subject is able to give consent/assent to participate in the protocol.

Listed below are acceptable medical conditions for inclusion in this protocol:

* Age greater than or equal to 18 years old
* Female gender
* Presence of a uterus
* Fall into one of the following categories:
* Healthy volunteers
* Hematologic patients:
* Whole bone marrow transplant recipients
* Peripheral blood stem cell transplant recipients
* Mesenchymal stem cell transplant recipients
* Bone marrow or stem cell donors
* Fully ablative transplant recipients
* Nonmyeloablative transplant recipients
* Cord blood transplant recipients

Rare, interesting, or unique reproductive phenotypes that may provide insight to endometrial function in health and disease:

* Asherman s syndrome
* Endometriosis
* Abnormal uterine bleeding
* Recurrent pregnancy loss
* Infertility
* Implantation failure
* Reproductive disorders

Exclusion Criteria

* Unable to comprehend the investigational nature of the protocol participation.
* Positive pregnancy test.
* Anticoagulation or known coagulopathy.
* Active gonorrhea or Chlamydia infections or pelvic inflammatory disease within the last 3 months.
* Previous hysterectomy or endometrial ablation procedure.
* Thrombocytopenia (\<50,000).
* Uterine or cervical cancer.
* Cervical stenosis.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alan H DeCherney, M.D.

Role: PRINCIPAL_INVESTIGATOR

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Bhanu NV, Trice TA, Lee YT, Gantt NM, Oneal P, Schwartz JD, Noel P, Miller JL. A sustained and pancellular reversal of gamma-globin gene silencing in adult human erythroid precursor cells. Blood. 2005 Jan 1;105(1):387-93. doi: 10.1182/blood-2004-04-1599. Epub 2004 Sep 14.

Reference Type BACKGROUND
PMID: 15367428 (View on PubMed)

Ogawa M, LaRue AC, Drake CJ. Hematopoietic origin of fibroblasts/myofibroblasts: Its pathophysiologic implications. Blood. 2006 Nov 1;108(9):2893-6. doi: 10.1182/blood-2006-04-016600. Epub 2006 Jul 13.

Reference Type BACKGROUND
PMID: 16840726 (View on PubMed)

Taylor HS. Endometrial cells derived from donor stem cells in bone marrow transplant recipients. JAMA. 2004 Jul 7;292(1):81-5. doi: 10.1001/jama.292.1.81.

Reference Type BACKGROUND
PMID: 15238594 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12-CH-0016

Identifier Type: -

Identifier Source: secondary_id

120016

Identifier Type: -

Identifier Source: org_study_id